Effect of Exendin-(9-39) on Glycemic Control in Subjects With Congenital Hyperinsulinism

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Congenital Hyperinsulinism

In brief

The purpose of this study is to determine if Exendin-(9-39), an antagonist of the glucagon-like peptide-1 (GLP-1) receptor with effects on the pancreatic beta cell, increases fasting blood glucose levels in subjects with congenital hyperinsulinism.

Key facts

Study ID

NCT00571324

Run by

Diva De Leon

People needed

9

Starts

2007-08-01

Expected to finish

2014-12-01

Last updated by the study team

2017-12-11

Who can join

Age: 7 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects with congenital hyperinsulinism

You may not qualify if…

• Acute medical illness
• History of other systemic chronic disease such as cardiac failure, renal insufficiency, hepatic insufficiency, chronic obstructive pulmonary disease, anemia, or uncontrolled hypertension
• Pregnancy
• Diabetes mellitus
• Use of medications that affect glucose metabolism, such as glucocorticoids, beta agonists, diazoxide and octreotide.
• Subjects will be eligible to participate 48 hrs after the last dose of octreotide and 72 hrs after last dose of diazoxide

Where it is running

• The Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.